Acrivon Therapeutics's three largest insider shareholders as of August 04, 2026 are Capital Management, L.P. Ra (Director, 11.80Mn shares), Capital Management, L.P. Ra (Director, 7.91Mn shares), Ltd Chione (TenPercentOwner, 3.85Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Advisors Llc Perceptive | - | 0 | 3,104,139 | 01 May, 2025 |
| Capital Management, L.P. Ra | - | 0 | 11,803,094 | 23 Apr, 2026 |
| Ltd Chione | - | 3,848,632 | 0 | 28 Jun, 2023 |
| Biomedical Innovation Master Investors (Cayman) I L.P. Wellington | - | 888,130 | 0 | 21 Nov, 2022 |
| Mary Miller | Chief Legal Officer | 33,679 | 0 | 18 Feb, 2026 |
| Rasmus Holm-Jorgensen | Chief Financial Officer | 26,088 | 0 | 19 Feb, 2025 |
| Peter Blume-Jensen | President And Ceo | 2,080,204 | 0 | 24 Feb, 2026 |
| Kristina Masson | Evp Business Operations | 0 | 2,370,097 | 16 Nov, 2022 |
| Erick Gamelin | Chief Development Officer | 14,812 | 0 | 18 Feb, 2026 |
| Eric Devroe | Chief Operating Officer | 74,585 | 0 | 18 Feb, 2026 |
| Katharine Peterson | Chief Accounting Officer | 4,006 | 0 | 18 Feb, 2026 |
| Adam D. Levy | Chief Financial Officer | 20,983 | 0 | 16 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 22 Apr, 2026 | Capital Management, L.P. Ra | Common Stock | A | 3,888,888 | $1.80 | 11,803,094 | I | A |
| 17 Apr, 2026 | Mary Miller | Common Stock | D | 558 | $1.78 | 33,121 | D | F |
| 01 Mar, 2026 | Adam D. Levy | Stock Option (Right to Buy) | A | 132,925 | $0.00 | 132,925 | D | A |
| 01 Mar, 2026 | Peter Blume-Jensen | Stock Option (Right to Buy) | A | 417,210 | $0.00 | 417,210 | D | A |
| 01 Mar, 2026 | Erick Gamelin | Stock Option (Right to Buy) | A | 94,946 | $0.00 | 94,946 | D | A |
| 01 Mar, 2026 | Eric Devroe | Stock Option (Right to Buy) | A | 186,728 | $0.00 | 186,728 | D | A |
| 01 Mar, 2026 | Eric Devroe | Stock Option (Right to Buy) | A | 186,728 | $0.00 | 186,728 | D | A |
| 01 Mar, 2026 | Erick Gamelin | Stock Option (Right to Buy) | A | 94,946 | $0.00 | 94,946 | D | A |
| 01 Mar, 2026 | Katharine Peterson | Stock Option (Right to Buy) | A | 31,900 | $0.00 | 31,900 | D | A |
| 01 Mar, 2026 | Adam D. Levy | Stock Option (Right to Buy) | A | 132,925 | $0.00 | 132,925 | D | A |
| 01 Mar, 2026 | Erick Gamelin | Stock Option (Right to Buy) | A | 94,946 | $0.00 | 94,946 | D | A |
| 01 Mar, 2026 | Erick Gamelin | Stock Option (Right to Buy) | A | 94,946 | $0.00 | 94,946 | D | A |
| 01 Mar, 2026 | Peter Blume-Jensen | Stock Option (Right to Buy) | A | 417,210 | $0.00 | 417,210 | D | A |
| 01 Mar, 2026 | Peter Blume-Jensen | Stock Option (Right to Buy) | A | 417,210 | $0.00 | 417,210 | D | A |
| 01 Mar, 2026 | Eric Devroe | Stock Option (Right to Buy) | A | 186,728 | $0.00 | 186,728 | D | A |
| 01 Mar, 2026 | Katharine Peterson | Stock Option (Right to Buy) | A | 31,900 | $0.00 | 31,900 | D | A |
| 01 Mar, 2026 | Adam D. Levy | Stock Option (Right to Buy) | A | 132,925 | $0.00 | 132,925 | D | A |
| 01 Mar, 2026 | Adam D. Levy | Stock Option (Right to Buy) | A | 132,925 | $0.00 | 132,925 | D | A |
| 01 Mar, 2026 | Katharine Peterson | Stock Option (Right to Buy) | A | 31,900 | $0.00 | 31,900 | D | A |
| 01 Mar, 2026 | Peter Blume-Jensen | Stock Option (Right to Buy) | A | 417,210 | $0.00 | 417,210 | D | A |